PT  - JOURNAL ARTICLE
AU  - Vouyiouklis, Mary
TI  - Canagliflozin: Improving diabetes by making urine sweet
AID  - 10.3949/ccjm.80a.13053
DP  - 2013 Nov 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 683--687
VI  - 80
IP  - 11
4099  - http://www.ccjm.org/content/80/11/683.short
4100  - http://www.ccjm.org/content/80/11/683.full
SO  - Cleve Clin J Med2013 Nov 01; 80
AB  - Canagliflozin is the first sodium-glucose cotransport 2 (SGLT2) inhibitor approved in the United States for treating type 2 diabetes mellitus. This drug blocks reabsorption of glucose in the proximal tubule, lowering the renal threshold for glucose and thereby increasing glucose excretion. Its novel mechanism of action is insulin-independent. Trials have demonstrated reductions in fasting glucose and hemoglobin A1c levels, with the added benefit of weight loss. The adverse effects most often reported include genital yeast infections and urinary tract infections. Ongoing trials will further elucidate possible long-term risks of this drug.